

# Dianorm<sup>®</sup> XR


Metformin Extended Release

Once daily

Simple to **START** with  
Simple to **STAY** with

- **New Patient:**  
Usual starting dose is Dianorm XR 500mg once daily with evening meal  
Dosage increases by increments of 500mg weekly
- **Patients on Metformin just shift to Dianorm XR with evening meal**
- **Maximum recommended dosage for Dianorm XR is 2000 mg with the evening meal**

**Dianorm<sup>®</sup> XR is bioequivalent to the innovator product**



1. David M Nathan, MD et al. Management of hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. Diabetes Care. 2006;29(8): 1963-1972  
 2. Cynthia R. Ong, MD et al. Long-Term Efficacy of Metformin Therapy in nonobese Individuals With Type 2 Diabetes. Diabetes Care. 2006;29(11): 2361-2364  
 3. Oral Pharmacological Agents for Type 2. Diabetes: Sulfonylureas, Meglitides, Metformin, Thiazolidinediones, Glucosidase Inhibitors, and Emerging Approaches. Endotext.org  
 4. Sherwyn Schwartz, MD et al. Efficacy, Tolerability, and Safety of a novel Once-Daily Extended-Release Metformin in Patients With Type 2 Diabetes. Diabetes Care. 2006;29(4): 759-764

Before prescribing please consult physicians' circular.

® Registered trade name

Dianorm<sup>®</sup> XR manufactured by **BPI**

- State of the art manufacturing facility
- Certified European GMP
- ISO Certified



**CE GMP**

Benta Pharma Industries - Dbayeh, Lebanon

# Dianorm<sup>®</sup> XR

Metformin Extended Release



Improve  
the Standard  
of Care



BENTA PHARMA INDUSTRIES

- **Metformin** is recommended as initial pharmacologic therapy<sup>1</sup>

Clinical Efficacy of Pharmacological Therapies to treat Type 2 Diabetes when used as Monotherapy

Agent Class	↓ Fasting Plasma Glucose		↓ HbA <sub>1c</sub> (%)	Insulin	Lipids	Body Weight
	(mg/dl)	(mmol/l)				
Sulfonylureas	60 - 70	3.3 - 3.9	0.8 - 2.0	Increase	No effect	Increase
Meglitinides	65 - 75	3.6 - 4.2	0.5 - 2.0	Increase	No effect	Increase
Biguanide (Metformin)	50 - 70	2.8 - 3.9	1.5 - 2.0	Decrease	TG ↓ LDL ↓ HDL ↑	Decrease
α - Glucosidase inhibitors	25 - 30	1.9 - 2.2	0.7 - 1.0	No effect	No effect	No effect

Adapted from Oral Pharmacological Agents for type 2 Diabetes chapter 14.<sup>3</sup>

- **Metformin** is at least as efficacious in the nonobese as it is in the obese individuals with type 2 Diabetes<sup>2</sup>

- **Dianorm<sup>®</sup> XR** improves the standard of care in oral-stage diabetes management.

**Metformin**

- **Decreases HbA<sub>1c</sub>**<sup>3</sup>
- **Has favorable lipid profile**<sup>3</sup>
- **Decrease body weight**<sup>3</sup>

- **Dianorm<sup>®</sup> XR** enable high dose without increase in adverse effects.

No increase in adverse events was observed with **Metformin XR** 2000mg once daily versus metformin immediate release 1500mg divided daily dose<sup>4</sup>

- **Dianorm<sup>®</sup> XR** encourages high treatment adherence with once-daily dosing<sup>4</sup>

97.2% of patients adhered to **Metformin XR** 2000mg once daily in a 24 week